Edward Lin

HealOMed Scientific, Inc.™ (HMS) is an innovation-driven manufacturer of proprietary, leading-edge medical technologies in respiratory care. The COVID-19 pandemic was projected by Harvard economists to cost the U.S. $16 TRILLION, with rehabilitation costs (for post-COVID complications) of $8.5 TRILLION (https://jamanetwork.com/journals/jama/fullarticle/2771764). This October 2020 report in JAMA was prior to the horrendous spike of winter 2020 and the delta variant surge of 2021. In Nov. 2021, HMS will launch the SentriO Oxy™, a super-oxygenating mask system that provides SUPERIOR oxygenation over the 60 LPM HFNC yet consumes only 16% of O2—as low as 5 LPM for a 70-kg/154-lb adult. At only 10 LPM O2, it delivers over 80% alveolar O2 concentration and achieves 99% oxygen saturation when HFNC at 60 LPM can only achieve 92%. Not only does SentriO Oxy™ save 72,000 liters of O2 per patient per day, it also enables hypoxic COVID patients to be protected and treated at home, and avert hypoxia-associated cardiopulmonary, cerebrovascular and other organ damages. The requirement for high O2 flow therapy has precipitated a national O2 crisis. (cf. paper from the Johns Hopkins Center for Health Security https://www.centerforhealthsecurity.org/resources/COVID-19/COVID-19-resources/210126-oxygen-memo.pdf). For developing nations with a limited O2 supply, the situation is dire as the endless replenishment of empty O2 tanks is tenuous and unreliable. Tank O2 costs 10X more and has bankrupted innumerable families while providing dismal outcome. The versatile and effective SentriO Oxy™ is FDA-cleared and will eliminate hospital overcrowding, reduce work burden of healthcare personnel, cut hospital as well as third-party payor expense and benefit patients and their families. Considering the health economics of prevention vs. remediation, it is clear that SentriO Oxy is a vital tool in reducing COVID mortality and morbidity. Contact support@healomed.com

HealO Medical® is an ingenuity-driven medical device company with award-winning patented and patent-pending game-changing technologies in advanced wound care. Based on reimbursement data from the US Wound Registry, the annual treatment cost of 6.5 million chronic wounds exceeds $50 billion. Because chronic wounds are confronted with two difficult obstacles: not enough blood flow and not enough oxygen, the average healing time of chronic wounds is a protracted, often painful 23 weeks. Wounds inflict untold human sufferings on patients and their families, . HealO's flagship product, named O-ACE-Sys® (pronounced "Oasis"), enables substantial increases in blood flow and tissue oxygenation, thereby accelerating healing at rates previously unattainable . O-ACE-Sys has won national and international awards, including a top-level $1.5M innovation award. HealO has received multiple US and international patents with a pipeline of pending patent applications. HealO's mission is to reduce patient suffering and cut healthcare cost by providing the most advanced therapies for accelerated healing of complex or chronic wounds without painful dressing changes. It is also developing innovative products for the prevention of surgical site infections (SSIs) and scarring. In response to the COVID-19 pandemic, I have invented the SentriO oxygenator which enables COVID patients to recover at home while breathing spontaneously and receiving high oxygen in the lung alveoli, comparable to that from a ventilator—but without the barotrauma and high costs. It may protect COVID patients from the hypoxia-associated multi-organ failure and hematologic and neurologic complications.

ITC is a privately held research and development company of diverse intellectual properties, creating innovative cost-effective solutions for the medical, pharmaceutical, consumer products, automotive and mobile communications industries. Portfolios of inventions in each of the above sectors are available for licensing, joint venture development or outright purchase.